MBX Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- MBX Biosciences Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Carmel
- Headquarters state / province
- Indiana
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MBX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001776111
Board of directors
- Since 2024
- Since 2024
-
James M. Cornelius · DirectorSince 2024
-
Laurie Stelzer · DirectorSince 2026
-
Ora H. Pescovitz · DirectorSince 2024
-
P. Kent Hawryluk · Director · President & CEOSince 2024
-
Patrick J. Heron · DirectorSince 2024
-
Steven L. Hoerter · Director · President and CEOSince 2025
-
Steven Ryder · DirectorSince 2024
-
Tiba Aynechi · DirectorSince 2024
Chief executives
Steven L. Hoerter
· President and CEO
Dates unknown
P. Kent Hawryluk
· President & CEO
Since September 2024
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
80.8%
-
88.4%
Board connections
6 of this board's directors also sit on 20 other boards.
- via Carl L. Gordon
- via Patrick J. Heron
- via Carl L. Gordon
- via Carl L. Gordon
- via Steven L. Hoerter
- via Carl L. Gordon
- via Carl L. Gordon
- via Carl L. Gordon
- via Patrick J. Heron
- via Edward T. Mathers
- via Steven L. Hoerter
- via Laurie Stelzer
- via Edward T. Mathers
- via Carl L. Gordon
- via Edward T. Mathers
- via Laurie Stelzer
- via Tiba Aynechi
- via Laurie Stelzer
- via Edward T. Mathers
- via Steven L. Hoerter
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,063,385
- 3 purchases by 2 insiders
- Sold, last 12 months
- $2,734,604
- 5 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 4, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −370 | $65.77 | $24,335 |
| Aug 3, 2026 | Steven L. Hoerter Director, Officer (President and CEO) | Grant or award | +71,000 | — | — |
| Aug 3, 2026 | John W. Smither Officer (Chief Financial Officer) | Grant or award | +28,000 | — | — |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Option exercise | +55,000 | $10.46 | $575,300 |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −55,000 | $38.38 | $2,110,900 |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Option exercise | +15,003 | $16.00 | $240,048 |
| May 8, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −15,003 | $38.30 | $574,615 |
| May 6, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Open-market sale | −231 | $29.54 | $6,824 |
| May 6, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Open-market sale | −607 | $29.54 | $17,931 |
| May 1, 2026 | Steven L. Hoerter Director | Grant or award | +11,938 | — | — |
| Mar 13, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Open-market purchase | +18,500 | $28.41 | $525,585 |
| Feb 26, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Option exercise | +28,768 | $16.00 | $460,288 |
| Feb 2, 2026 | Azoulay Salomon Officer (Chief Medical Officer) | Grant or award | +15,000 | — | — |
| Feb 2, 2026 | Bartram Richard Officer (Chief Financial Officer) | Grant or award | +15,000 | — | — |
| Feb 2, 2026 | P. Kent Hawryluk Director, Officer (President & CEO) | Grant or award | +35,250 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.